Beacon Financial Advisory LLC Sells 751 Shares of Pfizer Inc. (NYSE:PFE)

Beacon Financial Advisory LLC lessened its stake in Pfizer Inc. (NYSE:PFEFree Report) by 2.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 28,494 shares of the biopharmaceutical company’s stock after selling 751 shares during the period. Beacon Financial Advisory LLC’s holdings in Pfizer were worth $820,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Worth Asset Management LLC acquired a new stake in Pfizer during the 1st quarter valued at approximately $29,000. Briaud Financial Planning Inc acquired a new stake in shares of Pfizer during the third quarter worth $30,000. GoalVest Advisory LLC raised its stake in Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the last quarter. Mizuho Securities Co. Ltd. bought a new position in Pfizer during the third quarter worth $34,000. Finally, VisionPoint Advisory Group LLC lifted its holdings in Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 1,047 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently weighed in on PFE. UBS Group lowered their price objective on Pfizer from $34.00 to $27.00 and set a “neutral” rating for the company in a research report on Thursday, December 14th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research note on Monday. Barclays lowered their target price on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a report on Thursday, December 14th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from, the company presently has an average rating of “Hold” and a consensus price target of $36.88.

View Our Latest Stock Report on Pfizer

Pfizer Price Performance

NYSE PFE opened at $27.68 on Wednesday. The company has a market cap of $156.74 billion, a PE ratio of 76.53, a price-to-earnings-growth ratio of 1.24 and a beta of 0.61. The company has a quick ratio of 0.69, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. The firm’s 50-day simple moving average is $27.43 and its two-hundred day simple moving average is $29.29. Pfizer Inc. has a 52 week low of $25.61 and a 52 week high of $42.22.

Pfizer (NYSE:PFEGet Free Report) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same period last year, the firm earned $1.14 EPS. Pfizer’s revenue for the quarter was down 41.3% on a year-over-year basis. Research analysts predict that Pfizer Inc. will post 2.22 earnings per share for the current year.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with's FREE daily email newsletter.